Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

GeoVax Labs, Inc.

NASDAQ: GOVX · Life Sciences · 6 alerts · CIK 832489

Share price
$2.02Close, Nov 16
Market cap
$1.1M
Shares outstanding
544.45KLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All GeoVax Labs, Inc. filings on SEC EDGAR ↗

4:03 PM ET 10-Q
Financial Results

GeoVax Labs Q3 2026 Results: Net Loss of $4.16M, Loss Narrows

GeoVax Labs, Inc. reported a net loss of $13.8 million for the nine months ended September 30, 2026, compared to $17.0 million in the prior year period. The company is prioritizing its GEO-MVA vaccine candidate for poxviruses and its Gedeptin oncology program, though both require additional financing to initiate upcoming Phase 3 and Phase 2 trials, respectively.

Key figure
Net loss $4.16M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.